CY1119907T1 - Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου - Google Patents
Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμουInfo
- Publication number
- CY1119907T1 CY1119907T1 CY20181100159T CY181100159T CY1119907T1 CY 1119907 T1 CY1119907 T1 CY 1119907T1 CY 20181100159 T CY20181100159 T CY 20181100159T CY 181100159 T CY181100159 T CY 181100159T CY 1119907 T1 CY1119907 T1 CY 1119907T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- chromon
- production
- component
- autism spectrum
- Prior art date
Links
- 208000029560 autism spectrum disease Diseases 0.000 title abstract 2
- 102000015554 Dopamine receptor Human genes 0.000 title 1
- 108050004812 Dopamine receptor Proteins 0.000 title 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 abstract 1
- 101150097070 Drd3 gene Proteins 0.000 abstract 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306726 | 2013-12-13 | ||
| EP14812465.4A EP3079688B1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use in the treatment of autism spectrum disorder |
| PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119907T1 true CY1119907T1 (el) | 2018-06-27 |
Family
ID=49883003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100159T CY1119907T1 (el) | 2013-12-13 | 2018-02-09 | Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10028948B2 (enExample) |
| EP (1) | EP3079688B1 (enExample) |
| JP (1) | JP6419826B2 (enExample) |
| KR (1) | KR102280530B1 (enExample) |
| CN (1) | CN105792824B (enExample) |
| AU (1) | AU2014363428B2 (enExample) |
| BR (1) | BR112016012552A8 (enExample) |
| CA (1) | CA2932791C (enExample) |
| CY (1) | CY1119907T1 (enExample) |
| DK (1) | DK3079688T3 (enExample) |
| ES (1) | ES2657706T3 (enExample) |
| HR (1) | HRP20180323T8 (enExample) |
| HU (1) | HUE036035T2 (enExample) |
| IL (1) | IL245996B (enExample) |
| LT (1) | LT3079688T (enExample) |
| MA (1) | MA39076A1 (enExample) |
| MX (1) | MX372922B (enExample) |
| MY (1) | MY172937A (enExample) |
| NO (1) | NO3079688T3 (enExample) |
| NZ (1) | NZ720868A (enExample) |
| PL (1) | PL3079688T3 (enExample) |
| PT (1) | PT3079688T (enExample) |
| RS (1) | RS56931B1 (enExample) |
| RU (2) | RU2686110C1 (enExample) |
| SA (1) | SA516371298B1 (enExample) |
| SI (1) | SI3079688T1 (enExample) |
| TN (1) | TN2016000213A1 (enExample) |
| UA (1) | UA117271C2 (enExample) |
| WO (1) | WO2015086836A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA104869C2 (uk) | 2008-07-16 | 2014-03-25 | Ріхтер Гедеон Нірт. | Фармацевтичні композиції, що містять ліганди рецептора дофаміну |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| CA3152645A1 (en) * | 2019-09-11 | 2021-03-18 | Oxford BioDynamics PLC | Diagnostic chromosome marker |
| KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2682953B1 (fr) | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
| EP1119563B1 (en) | 1998-10-08 | 2006-02-01 | SmithKline Beecham plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| EP1793671B1 (en) | 2004-09-20 | 2011-04-27 | Mount Sinai School of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| EP2263665A1 (en) * | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| FR2949465B1 (fr) | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| WO2011150380A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012157463A1 (en) * | 2011-05-13 | 2012-11-22 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device |
| FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 MX MX2016007612A patent/MX372922B/es active IP Right Grant
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en not_active Ceased
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko not_active Expired - Fee Related
- 2014-12-12 HR HRP20180323TT patent/HRP20180323T8/hr unknown
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en not_active Not-in-force
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123633T1 (el) | Ετεροκυκλικες ενωσεις και οι χρησεις αυτων | |
| EP3490539A4 (en) | NEW ORAL FORMULATION. | |
| CY1119907T1 (el) | Ενα παραγωγο χρωμονης ως ενας ανταγωνιστης του d3 υποδοχεα ντοπαμινης για τη χρηση του στην αντιμετωπιση διαταραχης του φασματος του αυτισμου | |
| HUE043440T2 (hu) | Policiklusos amidszármazékok mint CDK9 inhibitorok | |
| ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
| EP3542171A4 (en) | CURRENT DIVERSION MONITORING DEVICE | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| DK3458074T3 (da) | COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH | |
| EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
| HUE058009T2 (hu) | 1,3-Tiazol-2-il szubsztituált benzamid-származékok | |
| DK3089741T3 (da) | Farmaceutiske sammensætninger omfattende azd9291 | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| HUE042628T2 (hu) | Mono- vagy diszubsztituált indolok mint dengue vírus replikáció inhibitorok | |
| HRP20192197T8 (hr) | Derivati karbazola | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| PL3207149T3 (pl) | Kompozycja farmaceutyczna o zwiększonej stabilności | |
| BR112016018371A2 (pt) | derivado de indolona substituído com pirrol, método de preparação do mesmo, composição compreendendo o mesmo e uso do mesmo | |
| CL2019001038A1 (es) | Composición para el cuidado bucal. | |
| LT3389633T (lt) | Farmacinės kompozicijos, apimančios fenilaminopirimidino darinį | |
| IL251101A0 (en) | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof | |
| HRP20181112T1 (hr) | Supstituirani derivati azaspiro(4,5)dekana | |
| CL2019001624A1 (es) | Composición para el cuidado bucal. | |
| LT3140318T (lt) | Kv1.3 kalio kanalų antagonistai | |
| CL2019000323A1 (es) | Composición para el cuidado bucal. | |
| HRP20180940T1 (hr) | Derivati supstituiranog azaspiro(4,5)dekana |